This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

LipiGesic M Is The Only Recommended First-line Therapy For Acute Migraine That Has No Evidence Of Rebound Headache

Stocks in this article: PMBS

SCHOFIELD, Wis., Aug. 5, 2013 /PRNewswire/ -- PuraMed BioScience ®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that its product, LipiGesic ® M, a homeopathic formulation of feverfew and ginger that eliminates migraine pain and associated symptoms, is the only recommended first-line therapy for acute migraine in the retail market today that has shown no evidence of rebound or medication-overuse headache.

Rebound, or medication-overuse headaches typically result when a person suffering migraines takes an OTC pain reliever or prescription migraine medication more than twice a week. According to the American Headache Society, all acute treatments can produce a medication-over-use or rebound headache.

However, LipiGesic M is Not Associated With Rebound Headache.

In the article, Advances in Drug Development for Acute Migraine, published in Drugs medical journal in December 2012, the authors, including headache expert Dr. Roger Cady, said of LipiGesic M, "Advantages of this product include lower cost, OTC availability, and it is not likely to produce medication-overuse headache. It is an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options."

"To my knowledge, there have been no reported incidences of LipiGesic M causing a rebound headache, no matter how frequently a person uses it to treat migraine pain," said Russ Mitchell, CEO of PuraMed BioScience. "Migraineurs who rely on the commonly used prescription migraine medications and over-the-counter migraine formulations run a high risk for rebound headache, but our product, LipiGesic M, has been shown to have none of those effects.

"With the widespread incidence of rebound headache associated with migraine medications, and the increased number of Food and Drug Administration warnings associated with acetaminophen, it is personally fulfilling to offer a treatment for acute migraine that works as well as the top-selling triptan products, but without increasing health risks," said Mitchell. "Having watched a loved one suffer with migraine pain, I am thankful that I'm able to provide consumers with a product that stops migraines fast without the risk of further harm."

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs